These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 9689838)

  • 1. Tardive dyskinesia: dental prosthetic therapy.
    Sutcher H; Soderstrom J; Perry R; Das A
    Panminerva Med; 1998 Jun; 40(2):154-6. PubMed ID: 9689838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of orodental status to the intensity of orofacial tardive dyskinesia: an interdisciplinary and video-based assessment.
    Girard P; Monette C; Normandeau L; Pampoulova T; Rompré PH; de Grandmont P; Blanchet PJ
    J Psychiatr Res; 2012 May; 46(5):684-7. PubMed ID: 22386652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia.
    Damier P; Thobois S; Witjas T; Cuny E; Derost P; Raoul S; Mertens P; Peragut JC; Lemaire JJ; Burbaud P; Nguyen JM; Llorca PM; Rascol O;
    Arch Gen Psychiatry; 2007 Feb; 64(2):170-6. PubMed ID: 17283284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prosthetic dentistry in the treatment of movement disorders: dyskinesias and other neurological abnormalities.
    Sutcher H
    Med Hypotheses; 2001 Mar; 56(3):318-20. PubMed ID: 11359353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The management of a completely edentulous patient with tardive dyskinesia.
    Katz W; Kaner T; Carrion J; Goldstein GR
    Int J Prosthodont; 2010; 23(3):217-20. PubMed ID: 20552086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tardive dyskinesia in the course of antidepressant therapy: a prevalence study and review of the literature.
    Yassa R; Camille Y; Belzile L
    J Clin Psychopharmacol; 1987 Aug; 7(4):243-6. PubMed ID: 3624506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study.
    Lerner V; Kaptsan A; Miodownik C; Kotler M
    Clin Neuropharmacol; 1999; 22(4):241-3. PubMed ID: 10442256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution.
    Akbostanci MC; Atbaşoğlu EC; Balaban H
    Acta Neurol Belg; 1999 Sep; 99(3):176-81. PubMed ID: 10544725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
    Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
    Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.
    Inada T; Koga M; Ishiguro H; Horiuchi Y; Syu A; Yoshio T; Takahashi N; Ozaki N; Arinami T
    Pharmacogenet Genomics; 2008 Apr; 18(4):317-23. PubMed ID: 18334916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pro- and antioxidant processes in schizophrenics with tardive dyskinesia].
    Gałecki P; Pietras T; Florkowki A
    Psychiatr Pol; 2005; 39(6):1131-41. PubMed ID: 16526180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levetiracetam in tardive dyskinesia.
    Meco G; Fabrizio E; Epifanio A; Morgante F; Valente M; Vanacore N; Di Rosa AE; Morgante L
    Clin Neuropharmacol; 2006; 29(5):265-8. PubMed ID: 16960471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tardive dyskinesia: a review and current treatment options.
    Najib J
    Am J Ther; 1999 Jan; 6(1):51-60. PubMed ID: 10423647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tardive dyskinesia.
    Soares-Weiser K; Fernandez HH
    Semin Neurol; 2007 Apr; 27(2):159-69. PubMed ID: 17390261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients.
    Ulrich S; Sandmann U; Genz A
    Pharmacopsychiatry; 2005 Jul; 38(4):171-7. PubMed ID: 16025420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The convergent and divergent validity of the Matson Evaluation of Drug Side-effects (MEDS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS).
    Matson JL; Fodstad JC; Rivet TT
    J Intellect Dev Disabil; 2008 Dec; 33(4):337-44. PubMed ID: 19039694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
    Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
    Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.